The albino fish have lower survival rates than normal fish but dress-out percentages are nearly equal.Some wild cave fish have populations that are albinistic. The Mexican cave tetra is a species that has evolved specialized characteristics in a series of independent caves. One of these is albinism linked to the Oca2 gene, a known pigmentation gene, This trait has evolved independently in at least two caves. In Chondrichthyes
In the class Chondrichthyes, several species of naturally occurring albino rays and sharks have been recorded. Furthermore, an albino individual spotted ratfish (Hydrolagus colliei) from the order Chimaeriformes has been reported.Albinistic individuals of the following shark species have been reported:
Basking shark (Cetorhinus maximus) – 2 cases
Broadnose sevengill shark (Notorynchus cepedianus)
Great white shark (Carcharodon carcharias)
Grey smooth-hound (Mustelus californicus) – 2 cases
Japanese topeshark (Hemitriakis japanica)
Japanese wobbegong (Orectolobus japonicus)
Java shark (Carcharhinus amboinensis)
Leopard shark (Triakis semifasciata)
Narrownose smooth-hound (Mustelus schmitti)
Pigeye shark (Carcharhinus amboinensis)
Porbeagle (Lamna nasus)
Scalloped hammerhead shark (Sphyrna lewini)
Spiny dogfish (Squalus acanthias)
Tawny nurse shark (Nebrius ferigineus)
Tiger shark (Galeocerdo cuvier) – embryo
Whale shark (Rhincodon typus)
Whitespotted bamboo shark (Chiloscyllium plagiosum)
Zebra shark (Stegostoma fasciatum)A study published in 2006 reported albinistic individuals of the following ray species:
Bat ray (Myliobatis californica)
Common skate (Raja batis)
Common stingray (Dasyatis pastinaca)
Common torpedo (Torpedo torpedo)
Cownose ray (Rhinoptera bonasus)
Giant electric ray (Narcine entemedor)
Giant oceanic manta ray (Manta birostris)
Ocellate spot skate (Okamejei kenojei)
Southern stingray (Dasyatis americana)
Thornback ray (Raja clavata)
Cuckoo ray (Raja naevus)

In Hyperoartia
There are several reports of albino lampreys and it has been estimated that this occurs at a frequency of one in 100,000 normal individuals.
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions. Medical uses
In the European Union, sotrovimab is indicated for the treatment of COVID-19 in people aged twelve years of age and older and weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.Sotrovimab is given by intravenous infusion, preferably within 5 days of onset of COVID-19 symptoms. Development and mechanism of action
Sotrovimabs development began in December 2019, at Vir Biotechnology when Vir scientists first learned of the initial COVID-19 outbreak in China. Vir subsidiary Humabs BioMed had already compiled a library of frozen blood samples from patients infected with viral diseases, including two samples from patients infected with SARS-CoV-1. Vir scientists obtained samples of the novel SARS-CoV-2 virus and mixed them with various antibodies recovered from the old SARS-CoV-1 blood samples. The objective was to identify antibodies effective against both SARS-CoV-1 and SARS-CoV-2. This would imply that the antibodies were targeting highly conserved sequences and in turn would be more likely to remain effective against future variants of SARS-CoV-2.